U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C10H13FN5O7P
Molecular Weight 365.2117
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FLUDARABINE PHOSPHATE

SMILES

NC1=NC(F)=NC2=C1N=CN2[C@@H]3O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]3O

InChI

InChIKey=GIUYCYHIANZCFB-FJFJXFQQSA-N
InChI=1S/C10H13FN5O7P/c11-10-14-7(12)4-8(15-10)16(2-13-4)9-6(18)5(17)3(23-9)1-22-24(19,20)21/h2-3,5-6,9,17-18H,1H2,(H2,12,14,15)(H2,19,20,21)/t3-,5-,6+,9-/m1/s1

HIDE SMILES / InChI

Description

Fludarabine or fludarabine phosphate is a chemotherapy drug used in the treatment of hematological malignancies (cancers of blood cells such as leukemias and lymphomas). It is a purine analog, which interferes with DNA synthesis. Fludarabine phosphate is a fluorinated nucleotide analog of the antiviral agent vidarabine, 9-β-D-arabinofuranosyladenine (ara-A), that is relatively resistant to deamination by adenosine deaminase. Fludarabine (marketed as fludarabine phosphate under the trade name Fludara) is a chemotherapy drug used in the treatment of hematological malignancies. Fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. This metabolite appears to act by inhibiting DNA polymerase alpha, ribonucleotide reductase and DNA primase, thus inhibiting DNA synthesis. The mechanism of action of this antimetabolite is not completely characterized and may be multi-faceted.

CNS Activity

Originator

Approval Year

1991
113
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8297
Inhibitor
8297
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
FLUDARABINE PHOSPHATE

Approved Use

Fludarabine Phosphate Injection is indicated for the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen. The safety and effectiveness of Fludarabine Phosphate Injection in previously untreated or non-refractory patients with CLL have not been established. Important Limitations Fludarabine Phosphate Injection should not be used in patients with severe renal impairment (creatinine clearance less than 30 mL/min/1.73 m2).

Launch Date

2007
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
4.28 μM
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/17211431
30 mg/m² single, intravenous
dose: 30 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
FLUDARABINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
21.55 μM × h
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/17211431
30 mg/m² single, intravenous
dose: 30 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
FLUDARABINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
8.9 h
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/17211431
30 mg/m² single, intravenous
dose: 30 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
FLUDARABINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
20 h
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020038s033lbl.pdf
25 mg/m² 1 times / day multiple, intravenous
dose: 25 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
FLUDARABINE plasma
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
100 mg/m2 1 times / day multiple, intravenous
Highest studied dose
Dose: 100 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 100 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/2428488
unhealthy, 32 years (range: 19-59 years)
n = 2
Health Status: unhealthy
Condition: Acute Leukemia
Age Group: 32 years (range: 19-59 years)
Sex: M+F
Population Size: 2
Sources:
https://pubmed.ncbi.nlm.nih.gov/2428488
Other AEs: Leukopenia...
Other AEs:
Leukopenia (2 patients)
Sources:
https://pubmed.ncbi.nlm.nih.gov/2428488
40 mg/m2 1 times / day steady, intravenous
MTD
Dose: 40 mg/m2, 1 times / day
Route: intravenous
Route: steady
Dose: 40 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/2428488
unhealthy, 32 years (range: 19-59 years)
n = 11
Health Status: unhealthy
Condition: Acute Leukemia
Age Group: 32 years (range: 19-59 years)
Sex: M+F
Population Size: 11
Sources:
https://pubmed.ncbi.nlm.nih.gov/2428488
Sources:
https://pubmed.ncbi.nlm.nih.gov/2428488
20 mg/m2 1 times / day multiple, intravenous
MTD
Dose: 20 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 20 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/2452888
unhealthy, 55 years (range: 26-78 years)
Health Status: unhealthy
Age Group: 55 years (range: 26-78 years)
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/2452888
Sources:
https://pubmed.ncbi.nlm.nih.gov/2452888
45 mg/m2 1 times / day multiple, intravenous
Dose: 45 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 45 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/2452888
unhealthy, 55 years (range: 26-78 years)
n = 1
Health Status: unhealthy
Age Group: 55 years (range: 26-78 years)
Sex: M+F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/2452888
DLT: Myelosuppression...
Dose limiting toxicities:
Myelosuppression (1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/2452888
40 mg/m2 1 times / day steady, oral
Recommended
Dose: 40 mg/m2, 1 times / day
Route: oral
Route: steady
Dose: 40 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022273s000_MedR.pdf
Page: p. 61
unhealthy, 64 years (range: 30-75 years)
n = 81
Health Status: unhealthy
Age Group: 64 years (range: 30-75 years)
Sex: M+F
Population Size: 81
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022273s000_MedR.pdf
Page: p. 61
Disc. AE: Thrombocytopenia, Anemia hemolytic autoimmune...
AEs leading to
discontinuation/dose reduction:
Thrombocytopenia (1 patient)
Anemia hemolytic autoimmune (3 patients)
Pneumonia (1 patient)
Anemia (1 patient)
Foot drop (1 patient)
Sepsis (1 patient)
Bronchitis (1 patient)
Rash (1 patient)
Face edema (1 patient)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022273s000_MedR.pdf
Page: p. 61
25 mg/m2 1 times / day steady, intravenous
Recommended
Dose: 25 mg/m2, 1 times / day
Route: intravenous
Route: steady
Dose: 25 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022137lbl.pdf
unhealthy, adult
Health Status: unhealthy
Condition: B-cell chronic lymphocytic leukemia
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022137lbl.pdf
Other AEs: CNS toxicity, Hemolytic anemia...
Other AEs:
CNS toxicity
Hemolytic anemia
Pulmonary toxicity
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022137lbl.pdf
40 mg/m2 1 times / day steady, oral
Recommended
Dose: 40 mg/m2, 1 times / day
Route: oral
Route: steady
Dose: 40 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022273lbl.pdf
unhealthy, adult
Health Status: unhealthy
Condition: B-cell chronic lymphocytic leukemia
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022273lbl.pdf
Other AEs: CNS toxicity, Hemolytic anemia...
Other AEs:
CNS toxicity
Hemolytic anemia
Pulmonary toxicity
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022273lbl.pdf
AEs

AEs

AESignificanceDosePopulation
Leukopenia 2 patients
100 mg/m2 1 times / day multiple, intravenous
Highest studied dose
Dose: 100 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 100 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/2428488
unhealthy, 32 years (range: 19-59 years)
n = 2
Health Status: unhealthy
Condition: Acute Leukemia
Age Group: 32 years (range: 19-59 years)
Sex: M+F
Population Size: 2
Sources:
https://pubmed.ncbi.nlm.nih.gov/2428488
Myelosuppression 1 patient
DLT, Disc. AE
45 mg/m2 1 times / day multiple, intravenous
Dose: 45 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 45 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/2452888
unhealthy, 55 years (range: 26-78 years)
n = 1
Health Status: unhealthy
Age Group: 55 years (range: 26-78 years)
Sex: M+F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/2452888
Anemia 1 patient
Disc. AE
40 mg/m2 1 times / day steady, oral
Recommended
Dose: 40 mg/m2, 1 times / day
Route: oral
Route: steady
Dose: 40 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022273s000_MedR.pdf
Page: p. 61
unhealthy, 64 years (range: 30-75 years)
n = 81
Health Status: unhealthy
Age Group: 64 years (range: 30-75 years)
Sex: M+F
Population Size: 81
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022273s000_MedR.pdf
Page: p. 61
Bronchitis 1 patient
Disc. AE
40 mg/m2 1 times / day steady, oral
Recommended
Dose: 40 mg/m2, 1 times / day
Route: oral
Route: steady
Dose: 40 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022273s000_MedR.pdf
Page: p. 61
unhealthy, 64 years (range: 30-75 years)
n = 81
Health Status: unhealthy
Age Group: 64 years (range: 30-75 years)
Sex: M+F
Population Size: 81
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022273s000_MedR.pdf
Page: p. 61
Face edema 1 patient
Disc. AE
40 mg/m2 1 times / day steady, oral
Recommended
Dose: 40 mg/m2, 1 times / day
Route: oral
Route: steady
Dose: 40 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022273s000_MedR.pdf
Page: p. 61
unhealthy, 64 years (range: 30-75 years)
n = 81
Health Status: unhealthy
Age Group: 64 years (range: 30-75 years)
Sex: M+F
Population Size: 81
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022273s000_MedR.pdf
Page: p. 61
Foot drop 1 patient
Disc. AE
40 mg/m2 1 times / day steady, oral
Recommended
Dose: 40 mg/m2, 1 times / day
Route: oral
Route: steady
Dose: 40 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022273s000_MedR.pdf
Page: p. 61
unhealthy, 64 years (range: 30-75 years)
n = 81
Health Status: unhealthy
Age Group: 64 years (range: 30-75 years)
Sex: M+F
Population Size: 81
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022273s000_MedR.pdf
Page: p. 61
Pneumonia 1 patient
Disc. AE
40 mg/m2 1 times / day steady, oral
Recommended
Dose: 40 mg/m2, 1 times / day
Route: oral
Route: steady
Dose: 40 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022273s000_MedR.pdf
Page: p. 61
unhealthy, 64 years (range: 30-75 years)
n = 81
Health Status: unhealthy
Age Group: 64 years (range: 30-75 years)
Sex: M+F
Population Size: 81
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022273s000_MedR.pdf
Page: p. 61
Rash 1 patient
Disc. AE
40 mg/m2 1 times / day steady, oral
Recommended
Dose: 40 mg/m2, 1 times / day
Route: oral
Route: steady
Dose: 40 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022273s000_MedR.pdf
Page: p. 61
unhealthy, 64 years (range: 30-75 years)
n = 81
Health Status: unhealthy
Age Group: 64 years (range: 30-75 years)
Sex: M+F
Population Size: 81
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022273s000_MedR.pdf
Page: p. 61
Sepsis 1 patient
Disc. AE
40 mg/m2 1 times / day steady, oral
Recommended
Dose: 40 mg/m2, 1 times / day
Route: oral
Route: steady
Dose: 40 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022273s000_MedR.pdf
Page: p. 61
unhealthy, 64 years (range: 30-75 years)
n = 81
Health Status: unhealthy
Age Group: 64 years (range: 30-75 years)
Sex: M+F
Population Size: 81
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022273s000_MedR.pdf
Page: p. 61
Thrombocytopenia 1 patient
Disc. AE
40 mg/m2 1 times / day steady, oral
Recommended
Dose: 40 mg/m2, 1 times / day
Route: oral
Route: steady
Dose: 40 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022273s000_MedR.pdf
Page: p. 61
unhealthy, 64 years (range: 30-75 years)
n = 81
Health Status: unhealthy
Age Group: 64 years (range: 30-75 years)
Sex: M+F
Population Size: 81
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022273s000_MedR.pdf
Page: p. 61
Anemia hemolytic autoimmune 3 patients
Disc. AE
40 mg/m2 1 times / day steady, oral
Recommended
Dose: 40 mg/m2, 1 times / day
Route: oral
Route: steady
Dose: 40 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022273s000_MedR.pdf
Page: p. 61
unhealthy, 64 years (range: 30-75 years)
n = 81
Health Status: unhealthy
Age Group: 64 years (range: 30-75 years)
Sex: M+F
Population Size: 81
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022273s000_MedR.pdf
Page: p. 61
CNS toxicity
25 mg/m2 1 times / day steady, intravenous
Recommended
Dose: 25 mg/m2, 1 times / day
Route: intravenous
Route: steady
Dose: 25 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022137lbl.pdf
unhealthy, adult
Health Status: unhealthy
Condition: B-cell chronic lymphocytic leukemia
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022137lbl.pdf
Hemolytic anemia
25 mg/m2 1 times / day steady, intravenous
Recommended
Dose: 25 mg/m2, 1 times / day
Route: intravenous
Route: steady
Dose: 25 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022137lbl.pdf
unhealthy, adult
Health Status: unhealthy
Condition: B-cell chronic lymphocytic leukemia
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022137lbl.pdf
Pulmonary toxicity
25 mg/m2 1 times / day steady, intravenous
Recommended
Dose: 25 mg/m2, 1 times / day
Route: intravenous
Route: steady
Dose: 25 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022137lbl.pdf
unhealthy, adult
Health Status: unhealthy
Condition: B-cell chronic lymphocytic leukemia
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022137lbl.pdf
CNS toxicity
40 mg/m2 1 times / day steady, oral
Recommended
Dose: 40 mg/m2, 1 times / day
Route: oral
Route: steady
Dose: 40 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022273lbl.pdf
unhealthy, adult
Health Status: unhealthy
Condition: B-cell chronic lymphocytic leukemia
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022273lbl.pdf
Hemolytic anemia
40 mg/m2 1 times / day steady, oral
Recommended
Dose: 40 mg/m2, 1 times / day
Route: oral
Route: steady
Dose: 40 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022273lbl.pdf
unhealthy, adult
Health Status: unhealthy
Condition: B-cell chronic lymphocytic leukemia
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022273lbl.pdf
Pulmonary toxicity
40 mg/m2 1 times / day steady, oral
Recommended
Dose: 40 mg/m2, 1 times / day
Route: oral
Route: steady
Dose: 40 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022273lbl.pdf
unhealthy, adult
Health Status: unhealthy
Condition: B-cell chronic lymphocytic leukemia
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022273lbl.pdf
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
substrate
1737

inhibitor
1587
inhibitor
1767
inhibitor
1852

OverviewOther

Other InhibitorOther SubstrateOther Inducer
P-gp
1461

CYP1A2
1524

CYP2A6
707

CYP2C19
1478

CYP2E1
882
P-gp
1537

CYP1A2
1054
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP1A2
1692
 no
CYP2A6
739
 no
CYP2C19
1553
 no
CYP2C9
1819
 no
CYP2D6
1891
 no
CYP2E1
970
 no
CYP3A4
1925
 no
P-gp
1650
 no
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP1A2
1054
 no
CYP3A4
1737
 no
P-gp
1537
 weak
Sourcing

Sourcing

Vendor/AggregatorIDURL
3B Scientific (Wuhan) Corp
3B2-0955
http://www.3bsc.com/index/pro_info.php?id=41860
AA Blocks
AA0039N2
https://www.aablocks.com/goods/Goods/detail?id=AA0039N2
AEchem Scientific Corp., USA
AE1-015944
http://www.aechemsc.com/info_products/AE1-015944.php
AHH Chemical co.,ltd
MT-51811
http://www.ahhchemical.com/product/MT-51811.html
Aaron Chemicals
AR003AEU
http://www.aaronchem.com/21679-14-1
AbMole Bioscience
M2028
http://www.abmole.com/products/fludarabine.html
Achemo Scientific Limited
AC-15243
http://www.achemo.com/search/?Keyword= 21679-14-1
Achemtek
0104-023119
http://www.achemtek.com/21679-14-1
Active Biopharma
ABP000557
http://www.activebiopharma.com/21679-14-1
Allbio Pharm Co., Ltd
AD08014
http://www.allbiopharm.com/product/n/AD08014
AstaTech, Inc.
HG1007
http://www.astatechinc.com/CPSResult.php?CRNO=17780
Aurora Fine Chemicals LLC
A24.077.320
http://online.aurorafinechemicals.com/info?ID=A24.077.320
Aurora Fine Chemicals LLC
K16.603.080
http://online.aurorafinechemicals.com/info?ID=K16.603.080
Aurum Pharmatech LLC
S-6059
http://www.Aurumpharmatech.com/Product/ProductDetails/S_6059
AvaChem Scientific
2653
http://www.avachem.com/productSearch.asp?2653
Avantor Inc
100576-076
https://us.vwr.com/store/catalog/product.jsp?catalog_number=100576-076
BLD Pharm
BD11972
http://www.bldpharm.com/products/21679-14-1.html
BioChemPartner
BCP01383
http://www.biochempartner.com/21679-14-1-BCP01383
BioCrick
BCC2518
http://www.biocrick.com/Fludarabine-BCC2518.html
BroadPharm
BP-25389
https://www.broadpharm.com/web/product.php?catalog=BP-25389
CSNpharm
CSN10528
https://www.csnpharm.com/products/fludarabine.html
Chem Scene
CS-2133
http://www.chemscene.com/21679-14-1.html
ChemMol
97900454
http://www.chemmol.com/chemmol/97900454.html
Chemspace
CSSB00000743926
https://chem-space.com/CSSB00000743926
Combi-Blocks
QA-3101
http://www.combi-blocks.com/cgi-bin/find.cgi?QA-3101
DC Chemicals
DC5889
http://www.dcchemicals.com/product_show-Fludarabine.html
Enamine
Z802671516
https://www.enaminestore.com/catalog/Z802671516
Excenen
EX-A833
http://www.excenen.com/searchresultlist.php?id=21679-14-1
Glentham Life Sciences
GP0730
http://www.glentham.com/products/product/GP0730/
Hairui
HR129788
http://www.hairuichem.com/en/product/21679-14-1.html
Lab Network
LN00175758
https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00175758
Matrix Scientific
76060
https://www.matrixscientific.com/076060.html
MedChem Express
HY-B0069
https://www.medchemexpress.com/fludarabine.html
MuseChem
A001054
https://www.musechem.com/product/A001054.html
OChem
2832
http://www.ocheminc.com/index.php?act=psearch&pid=679F141
Oakwood
79410
http://www.oakwoodchemical.com/ProductsList.aspx?CategoryID=-2&txtSearch=64584&ExtHyperLink=1
Parchem
28968
http://www.parchem.com/chemical-supplier-distributor/Fludarabine-018968.aspx
Selleck Chemicals
S1491
http://www.selleckchem.com/products/Fludarabine(Fludara).html
Sigma-Aldrich
F2773_SIGMA
https://www.sigmaaldrich.com/catalog/product/sigma/f2773?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Smolecule
S528115
http://www.smolecule.com/products/s528115
Synblock Inc
SB19413
http://www.synblock.com/product/21679-14-1.html
Synchem UG and Co KG
67378
http://www.synchem.de/chemical_Fludarabine.html
THE BioTek
bt-268280
https://www.thebiotek.com/product/inhibitors/bt-268280
Tocris
3495
https://www.tocris.com/products/fludarabine_3495
VladaChem
VL281192-10MG
https://www.vladachem.com/product.php?products=21679-14-1
abcr GmbH
AB348142
http://www.abcr.com/shop/en/AB348142
eNovation Chemicals
D481187
http://www.enovationchem.com/productDetails.asp?productID=D481187
eNovation Chemicals
D961702
https://www.enovationchem.com/ProductDetails.asp?ProductID=D961702
eNovation Chemicals
Y0974205
https://www.enovationchem.com/ProductDetails.asp?ProductID=Y0974205
iChemical
EBD18913
http://www.ichemical.com/products/21679-14-1.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs
mcule
MCULE-2497721739
https://mcule.com/MCULE-2497721739/
PubMed

PubMed

TitleDatePubMed
In vitro biological activity of 9-beta-D-arabinofuranosyl-2-fluoroadenine and the biochemical actions of its triphosphate on DNA polymerases and ribonucleotide reductase from HeLa cells.
1982 Mar
Neurotoxicity associated with fludarabine and cytosine arabinoside chemotherapy for acute leukemia and myelodysplasia.
1993 Mar
Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia.
1993 Mar
Apoptosis induction with three nucleoside analogs on freshly isolated B-chronic lymphocytic leukemia cells.
1994 Dec
Fludarabine + Ara-C + G-CSF: cytotoxic effect and induction of apoptosis on fresh acute myeloid leukemia cells.
1994 Dec
Increased p21/WAF-1 and p53 protein levels following sequential three drug combination regimen of fludarabine, cytarabine and docetaxel induces apoptosis in human leukemia cells.
1998 Jul-Aug
Caspase 8 activation independent of Fas (CD95/APO-1) signaling may mediate killing of B-chronic lymphocytic leukemia cells by cytotoxic drugs or gamma radiation.
2001 Nov 1
Drug-loaded red blood cell-mediated clearance of HIV-1 macrophage reservoir by selective inhibition of STAT1 expression.
2003 Nov
Interactions of nucleoside analogs, caffeine, and nicotine with human concentrative nucleoside transporters 1 and 2 stably produced in a transport-defective human cell line.
2004 Apr
Adenine deoxynucleotides fludarabine and cladribine induce apoptosis in a CD95/Fas receptor, FADD and caspase-8-independent manner by activation of the mitochondrial cell death pathway.
2004 Dec 16
9-beta-D-arabinofuranosyl-2-fluoroadenine inhibits expression of vascular endothelial growth factor through hypoxia-inducible factor-1 in human ovarian cancer cells.
2004 Jul
A phase I and pharmacodynamic study of fludarabine, carboplatin, and topotecan in patients with relapsed, refractory, or high-risk acute leukemia.
2004 Oct 15
Functional characterization of novel human and mouse equilibrative nucleoside transporters (hENT3 and mENT3) located in intracellular membranes.
2005 Apr 22
Recurrent chemotherapy-induced tumor lysis syndrome (TLS) with renal failure in a patient with chronic lymphocytic leukemia - successful treatment and prevention of TLS with low-dose rasburicase.
2005 Dec
Resistance to 9-beta-D-arabinofuranosyl-2-fluoroadenine due to reduced incorporation into DNA from competition by excess deoxyadenosine triphosphate: implications for different sensitivities to nucleoside analogues.
2005 Jun
A highly sensitive high-performance liquid chromatography-mass spectrometry method for quantification of fludarabine triphosphate in leukemic cells.
2005 Jun 25
Alteration of DNA methylation status in K562 and MCF-7 cancer cell lines by nucleoside analogues.
2006
Characterization of the rat Na+/nucleoside cotransporter 2 and transport of nucleoside-derived drugs using electrophysiological methods.
2006 Dec
Phase I and pharmacokinetic study of oral fludarabine phosphate in relapsed indolent B-cell non-Hodgkin's lymphoma.
2006 Feb
Chronic lymphocytic leukaemia, synchronous small cell carcinoma and squamous neoplasia of the urinary bladder in a paraplegic man following long-term phenoxybenzamine therapy.
2006 Mar
MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells.
2006 May 15
Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL).
2006 May 15
Role of fludarabine in hematological malignancies.
2006 Sep
Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication.
2008 Jan 1
Differential effects of chemotherapeutic drugs versus the MDM-2 antagonist nutlin-3 on cell cycle progression and induction of apoptosis in SKW6.4 lymphoblastoid B-cells.
2008 May 15
Oral fludarabine and cyclophosphamide as front-line chemotherapy in patients with chronic lymphocytic leukemia. The impact of biological parameters in the response duration.
2008 Nov
Fatal acute liver failure due to reactivation of hepatitis B following treatment with fludarabine/cyclophosphamide/rituximab for low grade non-Hodgkin's lymphoma.
2008 Oct 27
Fludarabine in the treatment of chronic lymphocytic leukemia: a review.
2009 Feb
Valproate synergizes with purine nucleoside analogues to induce apoptosis of B-chronic lymphocytic leukaemia cells.
2009 Jan
Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis.
2015 May 18
Patents

Patents

JP2002541233A
400
JP2003503313A
14
JP2004523497A
81
JP2007524637A
8
JP2011512332A
13
JP2011525180A
180
JP4701159B2
70

Sample Use Guides

In Vivo Use Guide
Chronic Lymphocytic Leukemia (CLL): The recommended adult dose is 25 mg/m2 administered intravenously over a period of approximately 30 minutes daily for five consecutive days. Each 5-day course of treatment should commence every 28 days.
Route of Administration: Intravenous
In Vitro Use Guide
The growth of RPMI8226 and KM3 cells was suppressed by fludarabine treatment in a dose and time-dependent manner. After treatment with fludarabine for 24 h, the IC(50) for RPMI8226 cells was 2.13 µg/ml, and 0.36 µg/ml for KM3 cells. Apoptotic cells of RPMI8226 and KM3 increased in a dose- dependent manner after exposure to fludarabine for 24 h. Western blot analysis showed the activation of caspase-3 and PARP in the MM cells treated with fludarabine.
Name Type Language
FLUDARABINE PHOSPHATE
EP   JAN   MART.   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
USAN  
Official Name English
NSC-328002
Code English
FLUDARA
Brand Name English
FLUDARABINE 5'-MONOPHOSPHATE [MI]
Common Name English
FLUDARABINE PHOSPHATE [JAN]
Common Name English
FLUDARABINE PHOSPHATE [EP MONOGRAPH]
Common Name English
FLUDARABINE 5'-MONOPHOSPHATE
MI  
Common Name English
FLUDARABINE PHOSPHATE [USAN]
Common Name English
9-.BETA.-D-ARABINOFURANOSYL-2-FLUOROADENINE 5'-(DIHYDROGEN PHOSPHATE)
Common Name English
FLUDARABINE PHOSPHATE [VANDF]
Common Name English
2-F-ARA-AMP
Common Name English
FLUDARABINE PHOSPHATE [MART.]
Common Name English
FLUDARABINE PHOSPHATE [USP-RS]
Common Name English
FLUDARABINE PHOSPHATE [ORANGE BOOK]
Common Name English
NSC-312887
Code English
9H-PURIN-6-AMINE, 2-FLUORO-9-(5-O-PHOSPHONO-.BETA.-D-ARABINOFURANOSYL)-
Common Name English
FLUDARABINE MONOPHOSPHATE
Common Name English
FLUDARABINE PHOSPHATE [USP MONOGRAPH]
Common Name English
Fludarabine phosphate [WHO-DD]
Common Name English
OFORTA
Brand Name English
Classification Tree Code System Code
NCI_THESAURUS C1556
Created by admin on Fri Dec 15 15:26:26 GMT 2023 , Edited by admin on Fri Dec 15 15:26:26 GMT 2023
FDA ORPHAN DRUG 35889
Created by admin on Fri Dec 15 15:26:26 GMT 2023 , Edited by admin on Fri Dec 15 15:26:26 GMT 2023
FDA ORPHAN DRUG 250607
Created by admin on Fri Dec 15 15:26:26 GMT 2023 , Edited by admin on Fri Dec 15 15:26:26 GMT 2023
FDA ORPHAN DRUG 27688
Created by admin on Fri Dec 15 15:26:26 GMT 2023 , Edited by admin on Fri Dec 15 15:26:26 GMT 2023
NCI_THESAURUS C2150
Created by admin on Fri Dec 15 15:26:26 GMT 2023 , Edited by admin on Fri Dec 15 15:26:26 GMT 2023
Code System Code Type Description
DRUG BANK
DB01073
Created by admin on Fri Dec 15 15:26:26 GMT 2023 , Edited by admin on Fri Dec 15 15:26:26 GMT 2023
PRIMARY
EVMPD
SUB13897MIG
Created by admin on Fri Dec 15 15:26:26 GMT 2023 , Edited by admin on Fri Dec 15 15:26:26 GMT 2023
PRIMARY
DAILYMED
1X9VK9O1SC
Created by admin on Fri Dec 15 15:26:26 GMT 2023 , Edited by admin on Fri Dec 15 15:26:26 GMT 2023
PRIMARY
MERCK INDEX
m5427
Created by admin on Fri Dec 15 15:26:26 GMT 2023 , Edited by admin on Fri Dec 15 15:26:26 GMT 2023
PRIMARY Merck Index
RXCUI
25102
Created by admin on Fri Dec 15 15:26:26 GMT 2023 , Edited by admin on Fri Dec 15 15:26:26 GMT 2023
PRIMARY RxNorm
CAS
75607-67-9
Created by admin on Fri Dec 15 15:26:26 GMT 2023 , Edited by admin on Fri Dec 15 15:26:26 GMT 2023
PRIMARY
NCI_THESAURUS
C1102
Created by admin on Fri Dec 15 15:26:26 GMT 2023 , Edited by admin on Fri Dec 15 15:26:26 GMT 2023
PRIMARY
NSC
312887
Created by admin on Fri Dec 15 15:26:26 GMT 2023 , Edited by admin on Fri Dec 15 15:26:26 GMT 2023
PRIMARY
FDA UNII
1X9VK9O1SC
Created by admin on Fri Dec 15 15:26:26 GMT 2023 , Edited by admin on Fri Dec 15 15:26:26 GMT 2023
PRIMARY
PUBCHEM
30751
Created by admin on Fri Dec 15 15:26:26 GMT 2023 , Edited by admin on Fri Dec 15 15:26:26 GMT 2023
PRIMARY
NSC
328002
Created by admin on Fri Dec 15 15:26:26 GMT 2023 , Edited by admin on Fri Dec 15 15:26:26 GMT 2023
PRIMARY
USAN
T-29
Created by admin on Fri Dec 15 15:26:26 GMT 2023 , Edited by admin on Fri Dec 15 15:26:26 GMT 2023
PRIMARY
EPA CompTox
DTXSID2023060
Created by admin on Fri Dec 15 15:26:26 GMT 2023 , Edited by admin on Fri Dec 15 15:26:26 GMT 2023
PRIMARY
SMS_ID
100000090025
Created by admin on Fri Dec 15 15:26:26 GMT 2023 , Edited by admin on Fri Dec 15 15:26:26 GMT 2023
PRIMARY
ChEMBL
CHEMBL1096882
Created by admin on Fri Dec 15 15:26:26 GMT 2023 , Edited by admin on Fri Dec 15 15:26:26 GMT 2023
PRIMARY
DRUG CENTRAL
1189
Created by admin on Fri Dec 15 15:26:26 GMT 2023 , Edited by admin on Fri Dec 15 15:26:26 GMT 2023
PRIMARY
CHEBI
63599
Created by admin on Fri Dec 15 15:26:26 GMT 2023 , Edited by admin on Fri Dec 15 15:26:26 GMT 2023
PRIMARY
RS_ITEM_NUM
1272204
Created by admin on Fri Dec 15 15:26:26 GMT 2023 , Edited by admin on Fri Dec 15 15:26:26 GMT 2023
PRIMARY
ACTIVE MOIETY
Structure of FLUDARABINE
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966